DE69634499D1 - Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration - Google Patents

Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration

Info

Publication number
DE69634499D1
DE69634499D1 DE69634499T DE69634499T DE69634499D1 DE 69634499 D1 DE69634499 D1 DE 69634499D1 DE 69634499 T DE69634499 T DE 69634499T DE 69634499 T DE69634499 T DE 69634499T DE 69634499 D1 DE69634499 D1 DE 69634499D1
Authority
DE
Germany
Prior art keywords
phagocytes
mammal
methods
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634499T
Other languages
English (en)
Other versions
DE69634499T2 (de
Inventor
Michal Eisenbach-Schwartz
Orly Spiegler
L Hirschberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE69634499D1 publication Critical patent/DE69634499D1/de
Application granted granted Critical
Publication of DE69634499T2 publication Critical patent/DE69634499T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Braiding, Manufacturing Of Bobbin-Net Or Lace, And Manufacturing Of Nets By Knotting (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69634499T 1995-09-15 1996-09-12 Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration Expired - Lifetime DE69634499T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52884595A 1995-09-15 1995-09-15
US528845 1995-09-15
US08/695,351 US5800812A (en) 1995-09-15 1996-08-09 Methods of use of mononuclear phagocytes to promote axonal regeneration
US695351 1996-08-09
PCT/US1996/014578 WO1997009885A1 (en) 1995-09-15 1996-09-12 Compositions and methods of use of mononuclear phagocytes to promote axonal regeneration

Publications (2)

Publication Number Publication Date
DE69634499D1 true DE69634499D1 (de) 2005-04-21
DE69634499T2 DE69634499T2 (de) 2006-01-05

Family

ID=27062850

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634499T Expired - Lifetime DE69634499T2 (de) 1995-09-15 1996-09-12 Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration

Country Status (13)

Country Link
US (2) US5800812A (de)
EP (1) EP0952772B1 (de)
JP (1) JP4100707B2 (de)
AT (1) ATE290789T1 (de)
AU (1) AU714205B2 (de)
CA (1) CA2232262A1 (de)
DE (1) DE69634499T2 (de)
DK (1) DK0952772T3 (de)
ES (1) ES2241002T3 (de)
IL (1) IL123642A (de)
NZ (1) NZ319365A (de)
PT (1) PT952772E (de)
WO (1) WO1997009885A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267955B1 (en) * 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
IL134289A0 (en) 1997-08-04 2001-04-30 Univ California Methods for treating neurological deficits
US20010007657A1 (en) * 1997-08-04 2001-07-12 Reid James Steven Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
US7795202B2 (en) * 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
EP1080110A2 (de) * 1998-05-19 2001-03-07 Yeda Research And Development Co. Ltd. Verwendung von aktivierten t zellen, nervensystem-spezifischen antigene zur behandlund von erkrankungen des nervensystems
SE9802264D0 (sv) 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
US6541247B1 (en) 1998-06-25 2003-04-01 Neuronova Ab Method of isolating ependymal neural stem cells
IL125983A0 (en) * 1998-08-30 1999-04-11 Yeda Res & Dev Pharmaceutical composition comprising factor xiiia
CA2441434A1 (en) * 2001-03-12 2002-09-19 Institute Of Gene And Brain Science Remedies for nerve damages
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
EP1578199A2 (de) * 2002-06-14 2005-09-28 Yeda Research And Development Company, Ltd. Antigen-präsentierende zellen für die neuroprotektion und nervenregeneration
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis
CN102186970A (zh) * 2008-09-12 2011-09-14 克里奥普拉斯低温生物有限公司 缺血性组织的细胞疗法
ES2604356T3 (es) 2011-12-14 2017-03-06 Yeda Research And Development Co. Ltd. Subpoblación de monocitos humanos para el tratamiento de lesiones del sistema nervioso central
KR102257163B1 (ko) 2013-05-22 2021-05-27 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안질환 및 장애의 치료를 위한 인간 단핵구 하위집단

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157024A (en) * 1977-10-16 1992-10-20 Strategic Medical Research Corporation Method of enhancing the activity of phagocytes including macrophages, modulating the cellular or humoral immune response, and reducing the adverse effects of stress in warm blooded animals
IL71440A0 (en) * 1984-04-04 1984-07-31 Univ Ramot Composition for nerve regeneration
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
IL91459A0 (en) * 1989-08-28 1990-04-29 Yeda Res & Dev Oligodendrocyte inhibitory factor

Also Published As

Publication number Publication date
JPH11513370A (ja) 1999-11-16
EP0952772A1 (de) 1999-11-03
NZ319365A (en) 1999-08-30
ES2241002T3 (es) 2005-10-16
DK0952772T3 (da) 2005-07-18
AU714205B2 (en) 1999-12-23
IL123642A0 (en) 1998-10-30
JP4100707B2 (ja) 2008-06-11
IL123642A (en) 2005-08-31
EP0952772A4 (de) 2002-01-02
EP0952772B1 (de) 2005-03-16
CA2232262A1 (en) 1997-03-20
PT952772E (pt) 2005-07-29
WO1997009885A1 (en) 1997-03-20
AU7157296A (en) 1997-04-01
DE69634499T2 (de) 2006-01-05
US6117424A (en) 2000-09-12
ATE290789T1 (de) 2005-04-15
US5800812A (en) 1998-09-01

Similar Documents

Publication Publication Date Title
DE69634499D1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
DK1028737T3 (da) Humane mesenchymale stamceller fra perifert blod
ATE397457T1 (de) Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
DE69832402D1 (de) Erzeugung von hämatopoietischen zellen aus multipotenten neuronalen stammzellen
ATE358176T1 (de) Menschliche dnase
ES2113669T3 (es) Estimulacion del bronceado mediante fragmentos de adn.
ATE80790T1 (de) Zusammensetzung zur behandlung der haut.
ATE338813T1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE69634982D1 (de) Verfahren zur steigerung von hematopoietischen zellen
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
ES2183890T3 (es) Uso del factor de crecimiento de hepatocitos para in estimular la proliferacion y diferenciacion de celulas hematopoyeticas.
DE69933581D1 (de) Verwendung von humanem wachstumshormon zur vermehrung der anzahl zirkulierender cd34+ zellen, zur wiederherstellung des hämapoietischen- und des immunsystems nach myeloablativer oder antiblastischer therapie, bei transplantation oder re-infusion
MXPA02011592A (es) Composiciones de celulas dendriticas circulantes, humanas y metodos.
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
EP1100515A4 (de) Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
ATE263833T1 (de) Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition